Human(3612) Summary: This gene encodes an enyzme that dephosphorylates myo-inositol monophosphate to generate free myo-inositol, a precursor of phosphatidylinositol, and is therefore an important modulator of intracellular signal transduction via the production of the second messengers myoinositol 1,4,5-trisphosphate and diacylglycerol. This enzyme can also use myo-inositol-1,3-diphosphate, myo-inositol-1,4-diphosphate, scyllo-inositol-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. This enzyme shows magnesium-dependent phosphatase activity and is inhibited by therapeutic concentrations of lithium. Inhibition of inositol monophosphate hydroylosis and subsequent depletion of inositol for phosphatidylinositol synthesis may explain the anti-manic and anti-depressive effects of lithium administered to treat bipolar disorder. Alternative splicing results in multiple transcript variants encoding distinct isoforms. A pseudogene of this gene is also present on chromosome 8q21.13. [provided by RefSeq, Nov 2009]
Save up to 60% per TRCN when you buy a set with the same options.
MISSION® siRNAs have been designed using a world-class siRNA design algorithm licensed from Rosetta Inpharmatics, a leader in advanced siRNA research. The Rosetta-powered siRNA design algorithm has been optimized with over 3 years of continuous development for enhanced performance in RNAi applications. New and critical siRNA design rules incorporated into the latest algorithm lead to increased target specificity and knockdown for low abundance messages.
Validated MISSION® siRNAs have been functionally validated in Hela cells by Sigma scientists to Knockdown gene expression by 75% or greater. With Validated MISSION® siRNAs, we have done the upfront validation work, so that you do not have to.